Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines

被引:13
作者
Capeding, Maria Rosario [1 ]
Alberto, Edison R. [1 ]
Bouckenooghe, Alain [2 ]
Laot, Thelma M. [3 ]
Chansinghakul, Danaya [4 ]
Monfredo, Celine [5 ]
Machabert, Tifany [6 ]
Feroldi, Emmanuel [7 ]
机构
[1] Res Inst Trop Med, Muntinlupa, Philippines
[2] Sanofi Pasteur, Clin Sci & Med Affairs, Singapore, Singapore
[3] Sanofi Pasteur, Clin Sci, Taguig City, Philippines
[4] Sanofi Pasteur, Clin Sci, Bangkok, Thailand
[5] Sanofi Pasteur, Clin Programs, Marcy Letoile, France
[6] Soladis, Lyon, France
[7] Sanofi Pasteur, Global Clin Sci, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France
关键词
JE-CV; IMOJEV; live attenuated Japanese encephalitis vaccine; Philippines; Japanese encephalitis; IMMUNOGENICITY; SAFETY;
D O I
10.1093/infdis/jix601
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We assessed antibody persistence following booster vaccination with a Japanese encephalitis chimeric virus vaccine (JE-CV; IMOJEV) in JE-CV-primed children. In an open phase 3 trial, 349 children in the Philippines, who received JE-CV 2 years previously, received a booster dose. JE neutralizing antibody titers were assessed (50% plaque reduction neutralization test) annually for up to 5 years after booster vaccination. Seroprotection rates (percentage of children with titers >= 10 [1/dil]) and geometric mean titers (GMTs) were, respectively, 98.2% and 161 after 5 years. JE-CV booster induced long-lasting anamnestic immune response in JE-CV-primed children, with high sero-protection rates and GMTs over the accepted threshold for serological protection (10 [1/dil]).
引用
收藏
页码:567 / 571
页数:5
相关论文
共 15 条
  • [1] Yellow fever Japanese encephalitis chimeric viruses: Construction and biological properties
    Chambers, TJ
    Nestorowicz, A
    Mason, PW
    Rice, CM
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (04) : 3095 - 3101
  • [2] Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children
    Chokephaibulkit, Kulkanya
    Sirivichayakul, Chukiat
    Thisyakorn, Usa
    Pancharoen, Chitsanu
    Boaz, Mark
    Bouckenooghe, Alain
    Feroldi, Emmanuel
    [J]. VACCINE, 2016, 34 (46) : 5664 - 5669
  • [3] Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2-to 5-year-olds and Naive 12-to 24-month-olds Multicenter Randomized Controlled Trial
    Chokephaibulkit, Kulkanya
    Sirivichayakul, Chukiat
    Thisyakorn, Usa
    Sabchareon, Arunee
    Pancharoen, Chitsanu
    Bouckenooghe, Alain
    Gailhardou, Sophia
    Boaz, Mark
    Feroldi, Emmanuel
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (12) : 1111 - 1117
  • [4] Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization
    Feroldi, Emmanuel
    Boaz, Mark
    Yoksan, Sutee
    Chokephaibulkit, Kulkanya
    Thisyakorn, Usa
    Pancharoen, Chitsanu
    Monfredo, Celine
    Bouckenooghe, Alain
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (02) : 221 - 227
  • [5] Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children
    Feroldi, Emmanuel
    Rosario Capeding, Maria
    Boaz, Mark
    Gailhardou, Sophia
    Meric, Claude
    Bouckenooghe, Alain
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (04) : 889 - 897
  • [6] Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months Randomized, controlled phase 3 immunogenicity and safety trial
    Feroldi, Emmanuel
    Pancharoen, Chitsanu
    Kosalaraksa, Pope
    Watanaveeradej, Veerachai
    Phirangkul, Kerdpanich
    Capeding, Maria R.
    Boaz, Mark
    Gailhardou, Sophia
    Bouckenooghe, Alain
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (07) : 929 - 937
  • [7] Japanese Encephalitis Surveillance and Immunization - Asia and Western Pacific Regions, 2016
    Heffelfinger, James D.
    Li, Xi
    Batmunkh, Nyambat
    Grabovac, Varja
    Diorditsa, Sergey
    Liyanage, Jayantha B.
    Pattamadilok, Sirima
    Bahl, Sunil
    Vannice, Kirsten S.
    Hyde, Terri B.
    Chu, Susan Y.
    Fox, Kimberley K.
    Hills, Susan L.
    Marfin, Anthony A.
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (22): : 579 - 583
  • [8] Hombach J, 2005, VACCINE, V23, P5205, DOI [10.1016/j.vaccine.2005.07.002, 10.1016/j.vaccine.2004.11.040]
  • [9] Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children
    Janewongwirot, Pakpoom
    Puthanakit, Thanyawee
    Anugulruengkitt, Suvaporn
    Jantarabenjakul, Watsamon
    Phasomsap, Chayapa
    Chumket, Sompong
    Yoksan, Sutee
    Pancharoen, Chitsanu
    [J]. VACCINE, 2016, 34 (44) : 5279 - 5283
  • [10] Kosalaraksa P, 2017, PEDIATR INFECT DIS J, V36, pE108, DOI [10.1097/inf.0000000000001494, 10.1097/INF.0000000000001494]